During the past decade, Revmatologicky ustav conducted 43 clinical trials. In the 10-year time frame, 43 clinical trials started and 47 clinical trials were completed, i.e. on average, 109.3% percent of trials that started reached the finish line to date. In the past 5 years, 21 clinical trials started and 29 clinical trials were completed. i.e. 138.1% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Revmatologicky ustav" #1 sponsor was "Pfizer" with 22 trials, followed by "Eli Lilly and Company" with 6 trials sponsored, "Janssen Research & Development, LLC" with 6 trials sponsored, "Amgen" with 5 trials sponsored and "Bristol-Myers Squibb" with 5 trials sponsored. Other sponsors include 23 different institutions and companies that sponsored additional 28 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Revmatologicky ustav" #1 collaborator was "Incyte Corporation" with 3 trials as a collaborator, "OCT Clinical Trials" with 2 trials as a collaborator, "Gilead Sciences" with 1 trials as a collaborator, "Hexal AG" with 1 trials as a collaborator and "IQVIA Pvt. Ltd" with 1 trials as a collaborator. Other collaborators include -1 different institutions and companies that were collaborators in the rest 9 trials.

According to Clinical.Site data, the most researched conditions in "Revmatologicky ustav" are "Rheumatoid Arthritis" (21 trials), "Psoriatic Arthritis" (8 trials), "Arthritis, Rheumatoid" (7 trials), "Arthritis, Psoriatic" (6 trials) and "Lupus Erythematosus, Systemic" (5 trials). Many other conditions were trialed in "Revmatologicky ustav" in a lesser frequency.

Most popular intervention types in "Revmatologicky ustav" are "Drug" (64 trials), "Other" (7 trials) and "Biological" (6 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (33 trials), "Methotrexate" (6 trials), "Guselkumab" (5 trials), "Baricitinib" (4 trials) and "etanercept" (4 trials). Other intervention names were less common.

The vast majority of trials in "Revmatologicky ustav" are 68 trials for "All" genders, 1 trials for "Female" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "Revmatologicky ustav". undefined are not yet recruiting, 4 are recruiting, 6 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 51 completed trials in Revmatologicky ustav, undefined suspended trials, and 9 terminated clinical trials to date.

Out of the total trials that were conducted in Revmatologicky ustav, 0 "Phase 1" clinical trials were conducted, 25 "Phase 2" clinical trials and 35 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 8 trials, and there were also 0 trials that are defined as “Not Applicable".